English
Insider transactions
EDGARUROGEN PHARMA LTD.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-19.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 15 transactions, 125,343 shares
- Sum of shares × price per share: 4,772,742.29
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 63
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-08 Filed 2026-10-09 | Degnan Chris Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 4,483 | — | — | 6,763 | Direct (D) | No | F1
| Open filing 0001437749-26-032421 Read from the filing’s XML Dispute this row |
| 2026-10-08 Filed 2026-10-09 | Degnan Chris Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,202 | 36.69 | 80,791.38Derived: shares × price per share. Exact value 80791.38. | 4,561 | Direct (D) | No | F2
| Open filing 0001437749-26-032421 Read from the filing’s XML Dispute this row |
| 2026-10-08 Filed 2026-10-09 | Degnan Chris Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 4,483 | 0 | — | 4,484 | Direct (D) | No | F1, F3
| Open filing 0001437749-26-032421 Read from the filing’s XML Dispute this row |
| 2026-09-08 Filed 2026-09-09 | Smith Jason Drew Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,519 | 42.54 | 64,618.26Derived: shares × price per share. Exact value 64618.26. | 53,141 | Direct (D) | No | F2
| Open filing 0001437749-26-029963 Read from the filing’s XML Dispute this row |
| 2026-09-08 Filed 2026-09-09 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 871 | 42.92 | 37,383.32Derived: shares × price per share. Exact value 37383.32. | 59,882 | Direct (D) | No | F2
| Open filing 0001437749-26-029965 Read from the filing’s XML Dispute this row |
| 2026-09-07 Filed 2026-09-09 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,334 | — | — | 54,660 | Direct (D) | No | F1
| Open filing 0001437749-26-029963 Read from the filing’s XML Dispute this row |
| 2026-09-07 Filed 2026-09-09 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 3,334 | 0 | — | 0 | Direct (D) | No | F1, F3
| Open filing 0001437749-26-029963 Read from the filing’s XML Dispute this row |
| 2026-09-07 Filed 2026-09-09 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 1,667 | — | — | 60,753 | Direct (D) | No | F1
| Open filing 0001437749-26-029965 Read from the filing’s XML Dispute this row |
| 2026-09-07 Filed 2026-09-09 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 1,667 | 0 | — | 0 | Direct (D) | No | F1, F3
| Open filing 0001437749-26-029965 Read from the filing’s XML Dispute this row |
| 2026-08-26 Filed 2026-08-28 | Robinson James A. Jr. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 2,000 | — | — | 8,000 | Direct (D) | No | F1
| Open filing 0001437749-26-029175 Read from the filing’s XML Dispute this row |
| 2026-08-26 Filed 2026-08-28 | Robinson James A. Jr. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 2,000 | 0 | — | 0 | Direct (D) | No | F1
| Open filing 0001437749-26-029175 Read from the filing’s XML Dispute this row |
| 2026-08-20 Filed 2026-08-24 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 60,677 | 47.05 | 2,854,852.85Derived: shares × price per share. Exact value 2854852.85. | 59,086 | Direct (D) | No | F1
| Open filing 0001437749-26-028840 Read from the filing’s XML Dispute this row |
| 2026-07-09 Filed 2026-07-10 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10,000 | 40 | 400,000Derived: shares × price per share. Exact value 400000. | 119,763 | Direct (D) | Yes | F1, F2
| Open filing 0001437749-26-023290 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10,000 | 35.01 | 350,100Derived: shares × price per share. Exact value 350100.00. | 129,763 | Direct (D) | Yes | F1, F2
| Open filing 0001437749-26-021523 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Holden Stuart Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 20,000 | 0 | — | 20,000 | Direct (D) | No | F1
| Open filing 0001437749-26-021515 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | WEN LEANA Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,000 | 0 | — | 10,000 | Direct (D) | No | F1
| Open filing 0001437749-26-021511 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | WEN LEANA Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 8,000 | 0 | — | 8,000 | Direct (D) | No | F2, F3
| Open filing 0001437749-26-021511 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Belldegrun Arie Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 20,000 | 0 | — | 20,000 | Direct (D) | No | F1
| Open filing 0001437749-26-021509 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Robinson James A. Jr. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,000 | 0 | — | 10,000 | Direct (D) | No | F1
| Open filing 0001437749-26-021517 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Robinson James A. Jr. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 8,000 | 0 | — | 8,000 | Direct (D) | No | F2, F3
| Open filing 0001437749-26-021517 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | BUTITTA CYNTHIA M Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,000 | 0 | — | 10,000 | Direct (D) | No | F1
| Open filing 0001437749-26-021513 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | BUTITTA CYNTHIA M Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 8,000 | 0 | — | 8,000 | Direct (D) | No | F2, F3
| Open filing 0001437749-26-021513 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Wildman Daniel George Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,000 | 0 | — | 10,000 | Direct (D) | No | F1
| Open filing 0001437749-26-021519 Read from the filing’s XML Dispute this row |
| 2026-06-22 Filed 2026-06-24 | Wildman Daniel George Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 8,000 | 0 | — | 8,000 | Direct (D) | No | F2, F3
| Open filing 0001437749-26-021519 Read from the filing’s XML Dispute this row |
| 2026-06-08 Filed 2026-06-09 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 10,000 | — | — | 144,985 | Direct (D) | No | F1
| Open filing 0001437749-26-019964 Read from the filing’s XML Dispute this row |
| 2026-06-08 Filed 2026-06-09 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 5,222 | 27.30 | 142,560.6Derived: shares × price per share. Exact value 142560.60. | 139,763 | Direct (D) | No | F2
| Open filing 0001437749-26-019964 Read from the filing’s XML Dispute this row |
| 2026-06-08 Filed 2026-06-09 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 10,000 | 0 | — | 0 | Direct (D) | No | F1, F3
| Open filing 0001437749-26-019964 Read from the filing’s XML Dispute this row |
| 2026-05-26 Filed 2026-05-27 | Robinson James A. Jr. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 2,000 | — | — | 6,000 | Direct (D) | No | F1
| Open filing 0001437749-26-018442 Read from the filing’s XML Dispute this row |
| 2026-05-26 Filed 2026-05-27 | Robinson James A. Jr. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 2,000 | 0 | — | 2,000 | Direct (D) | No | F1
| Open filing 0001437749-26-018442 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10,000 | 30 | 300,000Derived: shares × price per share. Exact value 300000. | 134,985 | Direct (D) | Yes | F1, F2
| Open filing 0001437749-26-016104 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,654 | 19.69 | 52,257.26Derived: shares × price per share. Exact value 52257.26. | 52,934 | Direct (D) | No | F2
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,608 | 19.69 | 31,661.52Derived: shares × price per share. Exact value 31661.52. | 51,326 | Direct (D) | No | F2
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,217 | 19.69 | 63,342.73Derived: shares × price per share. Exact value 63342.73. | 55,588 | Direct (D) | No | F2
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-04 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,844 | 19.69 | 36,308.36Derived: shares × price per share. Exact value 36308.36. | 150,514 | Direct (D) | No | F1
| Open filing 0001437749-26-003040 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-04 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,843 | 19.69 | 36,288.67Derived: shares × price per share. Exact value 36288.67. | 148,671 | Direct (D) | No | F1
| Open filing 0001437749-26-003040 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-04 | Schoenberg Mark Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,686 | 19.69 | 72,577.34Derived: shares × price per share. Exact value 72577.34. | 144,985 | Direct (D) | No | F1
| Open filing 0001437749-26-003040 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-19 | Barrett Elizabeth A. Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 153,195 | 0 | — | 153,195 | Direct (D) | No | F1, F2
| Open filing 0001437749-26-004638 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,500 | — | — | 55,472 | Direct (D) | No | F1
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,333 | — | — | 58,805 | Direct (D) | No | F1
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 6,667 | — | — | 49,972 | Direct (D) | No | F1
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,500 | 0 | — | 5,500 | Direct (D) | No | F1, F5
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 3,333 | 0 | — | 6,667 | Direct (D) | No | F1, F3
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 6,667 | 0 | — | 0 | Direct (D) | No | F1, F4
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-11 | Smith Jason Drew Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 32,609 | 0 | — | 32,609 | Direct (D) | No | F1, F6
| Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-03 | Degnan Chris Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 32,609 | 0 | — | 32,609 | Direct (D) | No | F1, F2
| Open filing 0001437749-26-002841 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-03 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,333 | — | — | 145,692 | Direct (D) | No | F1
| Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-03 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 6,666 | — | — | 152,358 | Direct (D) | No | F1
| Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-03 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,334 | — | — | 142,359 | Direct (D) | No | F1
| Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-03 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 3,333 | 0 | — | 3,334 | Direct (D) | No | F1, F4
| Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row |
| 2026-01-31 Filed 2026-02-03 | Schoenberg Mark Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 6,666 | 0 | — | 13,334 | Direct (D) | No | F1, F2
| Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.
Showing 1–50 of 224
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 4,543,895 SH | 184,618,454 dollars | Unchanged Prior quarter: 4,543,895 | Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 3,108,202 SH | 126,286,247 dollars | Lower by 93,259 Prior quarter: 3,201,461 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| Kynam Capital Management, LP | 2,434,207 SH | 98,901,830 dollars | Unchanged Prior quarter: 2,434,207 | Open filing 0001907884-26-000017 Filed 2026-11-16 Dispute this row |
| Jefferies Financial Group Inc. Partly reported under another manager | 2,199,652 SH | 89,371,861 dollars | Unchanged Prior quarter: 2,199,652 | Open filing 0000096223-26-000034 Filed 2026-11-05 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 2,174,808 SH | 88,362,486 dollars | Lower by 401,555 Prior quarter: 2,576,363 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| ACORN CAPITAL ADVISORS, LLC | 1,648,420 SH | 66,975,305 dollars | Lower by 25,000 Prior quarter: 1,673,420 | Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row |
| Opaleye Management Inc. | 1,439,996 SH | 58,507,037 dollars | Unchanged Prior quarter: 1,439,996 | Open filing 0001420506-26-002880 Filed 2026-11-16 Dispute this row |
| AMERICAN CENTURY COMPANIES INC Partly reported under another manager | 1,375,304 SH | 55,878,693 dollars | Lower by 310,415 Prior quarter: 1,685,719 | Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row |
| D. E. Shaw Co., Inc. Partly reported under another manager | 1,283,889 SH | 52,164,410 dollars | Higher by 138,070 Prior quarter: 1,145,819 | Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,148,689 SH | 46,671,234 dollars | Lower by 153,290 Prior quarter: 1,301,979 | Open filing 0001420506-26-002577 Filed 2026-11-12 Dispute this row |
| ORBIMED ADVISORS LLC | 988,487 SH | 40,162,227 dollars | Higher by 312,300 Prior quarter: 676,187 | Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 975,787 SH | 39,646,226 dollars | Lower by 27,284 Prior quarter: 1,003,071 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 936,144 SH | 38,035,534 dollars | Lower by 572,403 Prior quarter: 1,508,547 | Open filing 0001172661-26-005367 Filed 2026-11-16 Dispute this row |
| MPM BIOIMPACT LLC | 909,691 SH | 36,960,745 dollars | Lower by 23,724 Prior quarter: 933,415 | Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 848,342 SH | 34,468,135 dollars | Higher by 28,508 Prior quarter: 819,834 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| Migdal Insurance Financial Holdings Ltd. Partly reported under another manager | 770,909 SH | 31,322,033 dollars | Unchanged Prior quarter: 770,909 | Open filing 0001178913-26-005061 Filed 2026-11-09 Dispute this row |
| Parkman Healthcare Partners LLC | 750,202 SH | 30,480,707 dollars | Higher by 576,138 Prior quarter: 174,064 | Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 617,513 SH | 25,086,227 dollars | Higher by 7,149 Prior quarter: 610,364 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Woodline Partners LP | 500,726 SH | 20,344,497 dollars | Unchanged Prior quarter: 500,726 | Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row |
| Boxer Capital Management, LLC | 500,000 SH | 20,315,000 dollars | Unchanged Prior quarter: 500,000 | Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row |
| Elmind Capital, LP | 491,100 SH | 19,953,393 dollars | Higher by 371,100 Prior quarter: 120,000 | Open filing 0001013594-26-001197 Filed 2026-11-16 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 462,075 SH | 18,774,107 dollars | Higher by 5,517 Prior quarter: 456,558 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 406,299 SH | 16,507,928 dollars | Higher by 257,336 Prior quarter: 148,963 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| ADAR1 Capital Management, LLC | 369,785 SH | 15,024,365 dollars | Higher by 117,390 Prior quarter: 252,395 | Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager | 366,973 SH | 14,910,113 dollars | Not in the prior quarter’s filings read | Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row |
| Walleye Capital LLC | 348,116 SH | 14,143,953 dollars | Not in the prior quarter’s filings read | Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row |
| Hennion Walsh Asset Management, Inc. | 309,584 SH | 12,578,398 dollars | Higher by 32,888 Prior quarter: 276,696 | Open filing 0002000324-26-005579 Filed 2026-10-13 Dispute this row |
| FEDERATED HERMES, INC. Partly reported under another manager | 305,217 SH | 12,400,967 dollars | Higher by 304,259 Prior quarter: 958 | Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 303,188 SH | 12,318,529 dollars | Lower by 1,382 Prior quarter: 304,570 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| NEXT CENTURY GROWTH INVESTORS LLC | 297,083 SH | 12,070,482 dollars | Not in the prior quarter’s filings read | Open filing 0001134007-26-000007 Filed 2026-11-13 Dispute this row |
| Schonfeld Strategic Advisors LLC | 295,809 SH | 12,018,718 dollars | Higher by 263,350 Prior quarter: 32,459 | Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row |
| OBERWEIS ASSET MANAGEMENT INC/ | 295,625 SH | 12,011,244 dollars | Not in the prior quarter’s filings read | Open filing 0001213900-26-120411 Filed 2026-11-16 Dispute this row |
| Qube Research Technologies Ltd | 287,222 SH | 11,669,830 dollars | Not in the prior quarter’s filings read | Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row |
| AQR CAPITAL MANAGEMENT LLC Partly reported under another manager | 283,615 SH | 11,523,279 dollars | Higher by 134,387 Prior quarter: 149,228 | Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 268,902 SH | 10,925,488 dollars | Higher by 162,210 Prior quarter: 106,692 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 266,218 SH | 10,816,436 dollars | Higher by 144,757 Prior quarter: 121,461 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| Nuveen, LLC Partly reported under another manager | 240,822 SH | 9,784,598 dollars | Higher by 148,720 Prior quarter: 92,102 | Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 235,848 SH | 9,582,503 dollars | Lower by 239,854 Prior quarter: 475,702 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| FMR LLC Partly reported under another manager | 230,871 SH | 9,380,292 dollars | Higher by 33,773 Prior quarter: 197,098 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| Soleus Capital Management, L.P. | 230,274 SH | 9,356,033 dollars | Lower by 599,536 Prior quarter: 829,810 | Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row |
| RICE HALL JAMES ASSOCIATES, LLC | 226,046 SH | 9,184,249 dollars | Lower by 74,604 Prior quarter: 300,650 | Open filing 0001172661-26-005283 Filed 2026-11-16 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 210,356 SH | 8,508,900 dollars | Higher by 170,812 Prior quarter: 39,544 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| SUPERSTRING CAPITAL MANAGEMENT LP | 184,392 SH | 7,491,847 dollars | Lower by 6,921 Prior quarter: 191,313 | Open filing 0001931118-26-000011 Filed 2026-11-16 Dispute this row |
| Russell Investments Group, Ltd. Partly reported under another manager | 183,076 SH | 7,438,417 dollars | Higher by 88,097 Prior quarter: 94,979 | Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row |
| ING GROEP NV | 180,000 SH | 91,665,000 dollars | Not in the prior quarter’s filings read | Open filing 0001140361-26-042914 Filed 2026-11-10 Dispute this row |
| WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager | 168,792 SH | 6,858,020 dollars | Higher by 53,430 Prior quarter: 115,362 | Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row |
| J. Goldman Co LP | 149,139 SH | 6,059,518 dollars | Lower by 63,636 Prior quarter: 212,775 | Open filing 0001412741-26-000004 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 128,297 SH | 5,212,707 dollars | Lower by 73 Prior quarter: 128,370 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| Squarepoint Ops LLC Partly reported under another manager | 117,199 SH | 4,761,795 dollars | Higher by 105,500 Prior quarter: 11,699 | Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row |
| Tidal Investments LLC Partly reported under another manager | 112,990 SH | 4,590,784 dollars | Higher by 11,153 Prior quarter: 101,837 | Open filing 0002000324-26-006122 Filed 2026-11-13 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- SG Americas Securities, LLC 2,052,906 SH
- Point72 Asset Management, L.P. 1,525,549 SH
- MENORA MIVTACHIM HOLDINGS LTD. 1,152,531 SH
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 387,074 SH
- Sixth Street Partners Management Company, L.P. 128,370 SH
- Ally Bridge Group (NY) LLC 69,183 SH
- Annandale Capital, LLC 45,425 SH
- Coastal Bridge Advisors, LLC 37,000 SH
- J. Goldman Co LP 34,000 SH
- ALGERT GLOBAL LLC 32,350 SH
- Jupiter Topco LLC 19,100 SH
- GROUP ONE TRADING LLC 18,000 SH
- CAPITAL FUND MANAGEMENT S.A. 17,585 SH
- GLENMEDE TRUST CO NA 17,206 SH
- Birchview Capital, LP 16,487 SH
- NEW YORK STATE COMMON RETIREMENT FUND 15,737 SH
- Verdad Advisers, LP 14,440 SH
- Integrated Wealth Concepts LLC 11,741 SH
- INTECH INVESTMENT MANAGEMENT LLC 9,660 SH
- JANE STREET GROUP, LLC 9,505 SH
- Main Street Financial Solutions, LLC 8,190 SH
- Baader Bank Aktiengesellschaft 8,000 SH
- DIADEMA PARTNERS LP 7,137 SH
- Quantbot Technologies LP 2,133 SH
- Persistent Asset Partners Ltd 1,790 SH
- Napier Financial, LLC 400 SH
- Quarry LP 36 SH
- NATIONAL BANK OF CANADA /FI/ 11 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share | 5.7 | 2,770,530 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0000947263-26-000091 Dispute this row |
| TD SECURITIES INC. Ordinary Shares, par value NIS 0.01 per share | 0.2 | 115,706 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0000947263-26-000091 Dispute this row |
| BlackRock, Inc. Common Stock | 6.3 | 3,058,648 | 09/30/2026 Filed 2026-10-27 | SCHEDULE 13G/AAmendment 1 | Open filing 0002012383-26-003732 Dispute this row |
| The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share | 6.7 | 3,269,957 | 06/30/2026 Filed 2026-08-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0000947263-26-000072 Dispute this row |
| TD SECURITIES INC. Ordinary Shares, par value NIS 0.01 per share | 0.2 | 101,306 | 06/30/2026 Filed 2026-08-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0000947263-26-000072 Dispute this row |
| The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share | 5.4 | 2,616,714 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000947263-26-000047 Dispute this row |
| TD SECURITIES INC. Ordinary Shares, par value NIS 0.01 per share | 0 | 1,306 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000947263-26-000047 Dispute this row |
| Paradigm BioCapital Advisors LP Ordinary Shares, par value NIS 0.01 per share | 3.5 | 1,703,949.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-062615 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Ordinary Shares, par value NIS 0.01 per share | 3.5 | 1,703,949.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-062615 Dispute this row |
| Senai Asefaw, M.D. Ordinary Shares, par value NIS 0.01 per share | 3.5 | 1,703,949.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-062615 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Ordinary Shares, par value NIS 0.01 per share | 3.1 | 1,501,473.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 2 | Open filing 0001104659-26-062615 Dispute this row |
| BlackRock, Inc. Common Stock | 5.2 | 2,519,771 | 03/31/2026 Filed 2026-04-27 | SCHEDULE 13G | Open filing 0002012383-26-001661 Dispute this row |
| The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share | 4.9 | 2,302,334 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0000947263-26-000006 Dispute this row |
| Paradigm BioCapital Advisors LP Ordinary Shares, par value NIS 0.01 per share | 9.0 | 4,216,084.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112620 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Ordinary Shares, par value NIS 0.01 per share | 9.0 | 4,216,084.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112620 Dispute this row |
| Senai Asefaw, M.D. Ordinary Shares, par value NIS 0.01 per share | 9.0 | 4,216,084.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112620 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Ordinary Shares, par value NIS 0.01 per share | 8.0 | 3,722,066.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112620 Dispute this row |
| The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share | 6.9 | 3,190,510 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G | Open filing 0000947263-25-000010 Dispute this row |
| Cowen Financial Products LLC Ordinary Shares, par value NIS 0.01 per share | 0 | 0 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001771015-25-000010 Dispute this row |
| Paradigm BioCapital Advisors LP Ordinary Shares, par value NIS 0.01 per share | 5.0 | 2,332,066.00 | 08/05/2025 Filed 2025-08-12 | SCHEDULE 13G | Open filing 0001104659-25-076875 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Ordinary Shares, par value NIS 0.01 per share | 5.0 | 2,332,066.00 | 08/05/2025 Filed 2025-08-12 | SCHEDULE 13G | Open filing 0001104659-25-076875 Dispute this row |
| Senai Asefaw, M.D. Ordinary Shares, par value NIS 0.01 per share | 5.0 | 2,332,066.00 | 08/05/2025 Filed 2025-08-12 | SCHEDULE 13G | Open filing 0001104659-25-076875 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Ordinary Shares, par value NIS 0.01 per share | 4.4 | 2,056,187.00 | 08/05/2025 Filed 2025-08-12 | SCHEDULE 13G | Open filing 0001104659-25-076875 Dispute this row |
| RA Capital Management, L.P. Ordinary Shares, par value NIS 0.01 per share | 0.0 | 0.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001415889-25-022035 Dispute this row |
| Peter Kolchinsky Ordinary Shares, par value NIS 0.01 per share | 0.0 | 0.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001415889-25-022035 Dispute this row |
| Rajeev Shah Ordinary Shares, par value NIS 0.01 per share | 0.0 | 0.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001415889-25-022035 Dispute this row |
| RA Capital Healthcare Fund, L.P. Ordinary Shares, par value NIS 0.01 per share | 0.0 | 0.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001415889-25-022035 Dispute this row |
| Morgan Stanley Ordinary Shares | 5.4 | 2,488,299 | 06/30/2025 Filed 2025-08-06 | SCHEDULE 13G | Open filing 0000895421-25-000471 Dispute this row |
| Soleus Capital Master Fund, L.P. Ordinary Shares, par value NIS 0.01 per share | 4.7 | 2,185,000.00 | 06/30/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-072156 Dispute this row |
| Soleus Capital, LLC Ordinary Shares, par value NIS 0.01 per share | 4.7 | 2,185,000.00 | 06/30/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-072156 Dispute this row |
| Soleus Capital Group, LLC Ordinary Shares, par value NIS 0.01 per share | 4.7 | 2,185,000.00 | 06/30/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-072156 Dispute this row |
| Soleus Capital Management, L.P. Ordinary Shares, par value NIS 0.01 per share | 4.7 | 2,185,000.00 | 06/30/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-072156 Dispute this row |
| Soleus GP, LLC Ordinary Shares, par value NIS 0.01 per share | 4.7 | 2,185,000.00 | 06/30/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-072156 Dispute this row |
| Guy Levy Ordinary Shares, par value NIS 0.01 per share | 4.7 | 2,185,000.00 | 06/30/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-072156 Dispute this row |
| Cowen Financial Products LLC Ordinary Shares, par value NIS 0.01 per share | 6.9 | 3,190,510 | 06/30/2025 Filed 2025-07-29 | SCHEDULE 13G/AAmendment 1 | Open filing 0001085146-25-004272 Dispute this row |
| BlackRock, Inc. Common Stock | 5.0 | 2,284,206 | 06/30/2025 Filed 2025-07-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0002052113-25-002462 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,481,460 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 17,836 |
| 2016 | 222,374 |
| 2017 | 211,722 |
| 2018 | 222,268 |
| 2019 | 215,153 |
| 2020 | 166,955 |
| 2021 | 249,834 |
| 2022 | 187,707 |
| 2023 | 229,670 |
| 2024 | 234,041 |
| 2025 | 235,520 |
| 2026 | 260,174 |
Filings made before the SEC required XML are listed, not extracted.